Federated Hermes Inc. Cuts Position in STERIS plc $STE

Federated Hermes Inc. reduced its stake in shares of STERIS plc (NYSE:STE) by 41.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 191,195 shares of the medical equipment provider’s stock after selling 137,115 shares during the period. Federated Hermes Inc. owned approximately 0.19% of STERIS worth $45,929,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of STE. Mediolanum International Funds Ltd increased its holdings in STERIS by 9.0% during the 2nd quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock valued at $14,883,000 after acquiring an additional 5,156 shares in the last quarter. Entropy Technologies LP grew its position in shares of STERIS by 282.2% in the second quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock valued at $2,186,000 after purchasing an additional 6,718 shares during the period. Vanguard Group Inc. increased its stake in shares of STERIS by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after acquiring an additional 205,276 shares during the last quarter. Foresight Group Ltd Liability Partnership acquired a new position in shares of STERIS in the 1st quarter valued at $25,958,000. Finally, KLP Kapitalforvaltning AS increased its stake in STERIS by 5.3% during the second quarter. KLP Kapitalforvaltning AS now owns 33,800 shares of the medical equipment provider’s stock worth $8,119,000 after acquiring an additional 1,700 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Buying and Selling at STERIS

In other STERIS news, VP Renato Tamaro sold 5,036 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. This represents a 46.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Julia Madsen sold 5,008 shares of STERIS stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the completion of the transaction, the vice president directly owned 10,710 shares of the company’s stock, valued at $2,806,020. This trade represents a 31.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,203 shares of company stock worth $6,624,667 in the last ninety days. 1.07% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have commented on STE. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

STERIS Trading Down 0.8%

NYSE STE opened at $261.29 on Tuesday. The company has a market capitalization of $25.65 billion, a price-to-earnings ratio of 37.54 and a beta of 1.01. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63. STERIS plc has a 12 month low of $200.98 and a 12 month high of $268.60. The company’s fifty day moving average price is $250.32 and its two-hundred day moving average price is $243.52.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.09. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a net margin of 12.07% and a return on equity of 14.43%. During the same quarter in the prior year, the business posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, research analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Tuesday, November 18th will be paid a dividend of $0.63 per share. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s dividend payout ratio (DPR) is 36.21%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.